CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2012		Dec. 31, 2011
Current assets
Cash	$ 534,046		$ 952,252
Prepaid drug product for testing	195,000		153,000
Other current assets	42,575		48,439
Total current assets	771,621		1,153,691
Other assets
Technology licenses - related party	2,500,374		2,868,877
Less Accumulated Amortization	(928,231)		(791,463)
Intangible Assets, Net (Excluding Goodwill), Total	1,572,143		2,077,414
TOTAL ASSETS	2,343,764		3,231,105
Current liabilities
Accounts payable	57,000		121,540
Accounts payable - related party	8,582		67,971
Accrued expense	137,662		46,082
Accrued expense - related party	26,000		41,000
Accrued license payments - related party	100,000		39,538
Total current liabilities	329,244		316,131
Long term debt	0		0
TOTAL LIABILITIES	329,244		316,131
Shareholders' Equity
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding	0		0
Common Stock, $.001 par value, 200,000,000 shares authorized 62,219,050 and 58,325,169 shares issued and outstanding as of 12/31/12 and 12/31/11, respectively	62,218		58,325
Additional paid in capital	13,321,075		12,405,395
Additional paid in capital for shares to be issued	762,510	[1]	0	[1]
Accumulated deficit during development stage	(12,131,283)		(9,548,746)
Total shareholders' equity	2,014,520		2,914,974
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	$ 2,343,764		$ 3,231,105

[1] Represents 2,541,700 shares of common stock